By playing an active role in your own healthcare, you have an opportunity to receive innovative, potentially life-extending treatment before it’s commercially available.


Medical researchers need real-world data to bring these innovative therapies to market, your participation in a trial can give more options to future patients.


In order to learn more about diseases and treatments researchers need a diverse patient population to participate in the trials. Your participation may benefit others like you.

As research opens new doors to finding ways to diagnose, prevent, treat, or cure disease and disability, clinical trial participation is essential to help find the answers.
You should talk to your doctor to determine if trial participation is right for you. Before deciding to participate, carefully consider risks and possible benefits. The specific risks associated with a research protocol are described in an informed consent document that includes details about the study, such as its purpose, how long it’s expected to last, tests or procedures that will be done as part of the research, and who to contact for further information. A member of the research team will explain the study requirements and answer any questions about the informed consent document.


The ENVISION Clinical Trial is studying the Navitor™ Transcatheter Aortic Valve Implantation (TAVI) System in patients with severe, symptomatic aortic stenosis who are deemed low or intermediate surgical risk. Approximately 1,300 patients will be studied at up to 80 medical centers in the United States and Canada.

CAUTION: The Navitor TAVI System (for ENVISION Clinical Trial indications) is an investigational device. Limited by Federal (U.S.) law to investigational use only.


For people with atrial fibrillation (AFib), irregular electrical impulses in the upper chambers can cause an increased risk for developing blood clots, which can lead to a stroke. The left atrial appendage can be a major source of blood clots in patients with AFib. The CATALYST clinical trial will evaluate the safety and effectiveness of the Amplatzer™ Amulet™ Left Atrial Appendage Occluder compared to the treatment of blood thinner medication in patients with non-valvular AFib who are at an increased risk for stroke and who are recommended for long-term blood thinner medication.

CAUTION: The Amplatzer Amulet device (for CATALYST indications) is an investigational device. Limited by Federal (U.S.) law to investigational use only.


The REPAIR MR Trial (Percutaneous MitraClip™ Device or Surgical Mitral Valve REpair in PAtients with PrImaRy Mitral Regurgitation who are Candidates for Surgery) is now underway, and will be studying 500 patients at up to 75 medical centers in the United States, Canada, and Europe.

This clinical trial will study the MitraClip™ Transcatheter Mitral Valve Repair system in patients with severe primary mitral regurgitation who are at moderate surgical risk and whose mitral valve (MV) has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. The objective of this trial is to compare the clinical outcomes of the MitraClip device versus surgical repair in patients with severe primary MR who are at moderate surgical risk.

CAUTION: MitraClip (for REPAIR MR indications) is an investigational device. Limited by Federal (U.S.) law to investigational use only.


We are committed to investing in clinical trials and evidence to continue building better solutions for patients worldwide and to build trust in the safety and performance of our portfolio of life-changing structural heart devices. With over 40 planned clinical trials in the Structural Heart division, we take great pride in building confidence for physicians and patients.

This page is intended to provide clinical trial information only. The products and procedures discussed on this page are currently in clinical study and are limited by Federal (U.S.) law to investigational use only.

Clinical Research

"What separates Structural Heart is an absolute dedication and passion to do clinical studies at the highest possible level.”

Neil Moat
Divisional Vice President, Medical Affairs and Chief Medical Officer

Diversity in Clinical Trials

"As an industry, we need to set new standards to make sure that our clinical trials remain representative of the people our products are designed to help.”

Barathi Sethuraman
Divisional Vice President, Global Clinical Affairs

MAT-2301099 v5.0 | Item approved for U.S. use only.

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2302755 v4.0  |   Item approved for U.S. use only.


To implant the device, your doctor inserts a narrow tube into a vein in your upper leg.